Rising covid cases unnerve investors
Rising covis cases and tighter measures to stem the spread of the virus are raising fears that the fragile economic recovery will quickly be derailed.
Share this:
European bourses start the trading steeply lower as the new week kicks off. Rising covis cases and tighter measures to stem the spread of the virus are raising fears that the fragile economic recovery will quickly be derailed. Fears of a double dip recession are overshadowing upbeat vaccine. Although reports that the UK government is considering reducing quarantine period for covid contacts is helping the FTSE, which hasn’t fallen as steeply as its European peers on the open.
The US and France recorded a record number of coronavirus cases, Spain announced a national curfew and Italy a partial lockdown. Meanwhile in the UK covid cases topped 23,000 with the North East and West seeing the biggest increase in cases.
Still, risk off is dominating as investors fret over the impact that tighter restrictive measures will have on economic growth. Riskier assets such as stocks are out of favour, whilst flows into safer havens such as the US Dollar are on the rise.
Not all bad news
News that the British government is considering a shorter isolation period, reduced from 14 days to 7 days for those who have been in contact with someone who tested positive is offering some support to the UK index, which hasn’t sold off as deeply on the open as its European counterparts
News that the Oxford University / AstraZeneca vaccine produces a robust immune response in elderly people, the group at highest risk is broadly being shrugged off by investors. As is news that the vaccine is likely to be distributed to NHS frontline workers and the most vulnerable in December.
News that the British government is considering a shorter isolation period, reduced from 14 days to 7 days for those who have been in contact with someone who tested positive is offering some support to the UK index, which hasn’t sold off as deeply on the open as its European counterparts
News that the Oxford University / AstraZeneca vaccine produces a robust immune response in elderly people, the group at highest risk is broadly being shrugged off by investors. As is news that the vaccine is likely to be distributed to NHS frontline workers and the most vulnerable in December.
A slow start to a busy week
Whilst covid is set to remain a key driver in the market this week, in addition to US elections and US stimulus negotiations, this week is also a key week for corporate releases with UK banks and 4 of the FAANGs reporting, in addition to other big names such as BP, Next, GSK just to mention a few.
Looking ahead it is a relatively slow start to the week with just IFO Business sentiment in focus.
Whilst covid is set to remain a key driver in the market this week, in addition to US elections and US stimulus negotiations, this week is also a key week for corporate releases with UK banks and 4 of the FAANGs reporting, in addition to other big names such as BP, Next, GSK just to mention a few.
Looking ahead it is a relatively slow start to the week with just IFO Business sentiment in focus.
FTSE Charts
The FTSE trades -0.6%. It trades below its 50, 100 & 200 SMA on the 4 hour chart and below a descending trendline which has been in place since early June – a bearish chart.
Immediate support can be seen at 5760, today’s low prior to 5715, last week’s low.
Immediate resistance is at 5855 50 SMA prior to 5910/20 region where the 100 & 200 SMA sit. A move above 5970 is needed to negate the current bearish trend.
European bourses start the trading steeply lower as the new week kicks off. Rising covis cases and tighter measures to stem the spread of the virus are raising fears that the fragile economic recovery will quickly be derailed. Fears of a double dip recession are overshadowing upbeat vaccine. Although reports that the UK government is considering reducing quarantine period for covid contacts is helping the FTSE, which hasn’t fallen as steeply as its European peers on the open.
The US and France recorded a record number of coronavirus cases, Spain announced a national curfew and Italy a partial lockdown. Meanwhile in the UK covid cases topped 23,000 with the North East and West seeing the biggest increase in cases.
Still, risk off is dominating as investors fret over the impact that tighter restrictive measures will have on economic growth. Riskier assets such as stocks are out of favour, whilst flows into safer havens such as the US Dollar are on the rise.
Not all bad news
News that the British government is considering a shorter isolation period, reduced from 14 days to 7 days for those who have been in contact with someone who tested positive is offering some support to the UK index, which hasn’t sold off as deeply on the open as its European counterparts
News that the Oxford University / AstraZeneca vaccine produces a robust immune response in elderly people, the group at highest risk is broadly being shrugged off by investors. As is news that the vaccine is likely to be distributed to NHS frontline workers and the most vulnerable in December.
News that the British government is considering a shorter isolation period, reduced from 14 days to 7 days for those who have been in contact with someone who tested positive is offering some support to the UK index, which hasn’t sold off as deeply on the open as its European counterparts
News that the Oxford University / AstraZeneca vaccine produces a robust immune response in elderly people, the group at highest risk is broadly being shrugged off by investors. As is news that the vaccine is likely to be distributed to NHS frontline workers and the most vulnerable in December.
A slow start to a busy week
Whilst covid is set to remain a key driver in the market this week, in addition to US elections and US stimulus negotiations, this week is also a key week for corporate releases with UK banks and 4 of the FAANGs reporting, in addition to other big names such as BP, Next, GSK just to mention a few.
Looking ahead it is a relatively slow start to the week with just IFO Business sentiment in focus.
Whilst covid is set to remain a key driver in the market this week, in addition to US elections and US stimulus negotiations, this week is also a key week for corporate releases with UK banks and 4 of the FAANGs reporting, in addition to other big names such as BP, Next, GSK just to mention a few.
Looking ahead it is a relatively slow start to the week with just IFO Business sentiment in focus.
FTSE Charts
The FTSE trades -0.6%. It trades below its 50, 100 & 200 SMA on the 4 hour chart and below a descending trendline which has been in place since early June – a bearish chart.
Immediate support can be seen at 5760, today’s low prior to 5715, last week’s low.
Immediate resistance is at 5855 50 SMA prior to 5910/20 region where the 100 & 200 SMA sit. A move above 5970 is needed to negate the current bearish trend.
Related tags:
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
EUR/USD, FTSE 100 Forecast: Two trades to watch 1507
EUR/USD rises after weaker US CPI, PPI up next. FTSE 100 falls as weak China GDP data hits miners.
FTSE 100, USD/JPY Forecast: Two trades to watch
FTSE eases modestly despite inflation unexpectedly holding steady. USD/JPY drifts lower ahead of the FOMC rate decision.
EUR/USD, FTSE 100 Forecast: Two trades to watch 21-05-26
EUR/USD slips below 1.16 as weak eurozone data weighs on sentiment. FTSE 100 slips as oil prices rebound and caution returns.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.